Your session is about to expire
← Back to Search
Unknown
PDI-320 Monad #2 for Rosacea
Phase 2
Waitlist Available
Research Sponsored by PreCision Dermatology, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 4 and week 8
Summary
This trial is testing a new treatment called PDI-320 and its parts in adults with rosacea. The goal is to see if it can safely reduce symptoms like redness and inflammation.
Eligible Conditions
- Rosacea
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, week 4 and week 8
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 4 and week 8
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Inflammation
Treatment "Success Rate" based on change in Investigator's Global Assessment (IGA)
Secondary study objectives
Absolute change in inflammatory lesion count (interim time points)
Change in erythema severity
Change in telangiectasia severity
+1 moreTrial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: PDI-320 Monad #2Experimental Treatment1 Intervention
Foam, twice daily for up to 12 weeks
Group II: PDI-320 Monad #1Experimental Treatment1 Intervention
Foam, twice daily for up to 12 weeks
Group III: PDI-320Experimental Treatment1 Intervention
Foam, twice daily for up to 12 weeks
Group IV: VehiclePlacebo Group1 Intervention
Foam, twice daily for up to 12 weeks
Find a Location
Who is running the clinical trial?
PreCision Dermatology, Inc.Lead Sponsor
1 Previous Clinical Trials
151 Total Patients Enrolled
Syd Dromgoole, PhDStudy DirectorTherapeutics, Inc.
4 Previous Clinical Trials
292 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger